In an interview about her long-term vision for the university with the Philadelphia Business Journal, Penn President Liz Magill mentions Penn’s breakthroughs in cell and gene therapy, including developments in CAR T cell therapy and mRNA vaccine technology. She also notes how startups affiliated with Penn raised $560 million and filed 929 patents, according to PCI’s FY22 report.
“I’m particularly proud of the role that research at Penn has played in the innovation ecosystem, in the economy here in Philadelphia, which I think is one of the reasons we are one of the top four bio cities,” Magill said. In terms of the future of innovation, Magill predicts that continued collaboration across disciplines will help to foster breakthroughs, new inventions and startup companies. Read the full article here.